CONTE LISA A 4
4 · Jaguar Health, Inc. · Filed Jun 26, 2025
Insider Transaction Report
Form 4
CONTE LISA A
DirectorSee Remarks
Transactions
- Disposition to Issuer
Convertible Promissory Note
2025-06-24$50000.00/sh−9,000$450,000,000→ 0 totalExercise: $5.55→ Common Stock (9,000 underlying) - Award
Warrant to Purchase Common Stock
2025-06-24+18,262→ 9,000 totalExercise: $2.70Exp: 2026-12-24→ Common Stock (18,262 underlying) - Award
Convertible Promissory Note
2025-06-24$50000.00/sh+9,462$473,100,000→ 9,462 totalExercise: $5.55→ Common Stock (9,462 underlying)
Footnotes (2)
- [F1]The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
- [F2]As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.